Today it was reported that the CTO of Seattle Genetics (NASDAQ: SGEN), Vaughn Himes, exercised options to sell 5,000 SGEN shares at $12.00 a share, for a total transaction value of $385K.
Following Vaughn Himes’ last SGEN Sell transaction on December 14, 2016, the stock climbed by 15.5%. In addition to Vaughn Himes, one other SGEN executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Seattle Genetics’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $170 million and quarterly net profit of $76.27 million. In comparison, last year the company earned revenue of $108 million and had a GAAP net loss of $56.36 million. Currently, Seattle Genetics has an average volume of 641K. The Company has a Price to Book ratio of 8.9959.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $79.14, reflecting a 1.0% upside.
The insider sentiment on Seattle Genetics has been negative according to 59 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
